Skip to main navigation
Ionis Pharmaceuticals Logo
Skip to content
  • About
    • Mission & Values
    • In The Community
    • Management
    • Board of Directors
    • Contact
  • R&D
    • Antisense Technology
      • Discovery Platform
      • Basic Science
      • Antisense Drugs
      • Medicinal Chemistry
      • Antisense Approaches
    • Intellectual Property
    • Strategic Alliances
      • Pharmaceutical Partners
      • Satellite Companies
  • Pipeline
  • Patients
    • Patient Resources
    • Clinical Trials
      • Drug Approval Process
  • Medical Professionals
    • ATTR Expanded Access Program
  • Investors & Media
    • News & Events
      • Press Releases
      • Archived Webcasts
      • Event Calendar
    • Corporate Governance
      • Board of Directors
      • Board Criteria
      • Director Compensation and Board Meeting Attendance
      • Committee Composition
      • Certificates of Incorporation
      • Bylaws
      • Code of Ethics
      • Clawback Policy
      • RSU Holding Guidelines
      • Annual Meeting
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Analyst Coverage
      • Ownership Profile
    • Financials
      • Annual Reports
      • SEC Filings
    • Shareholder Services
      • Investor FAQ
      • Information Request
    • Press Kit
  • Careers
    • Available Positions
      • Search Open Jobs
      • Browse Open Jobs
      • Edit Your Profile
      • View Submitted Applications
    • Culture & Core Principles
    • Benefits
    • Equal Opportunity
    • Intern Program
    • Post-Doctoral Program

Certificates of Incorporation

Date Documents
12/22/15
  • Add Files
    12.21.2015 Certificate of Incorporation - DE - Amendment 1.1 MB
07/10/14
  • Add Files
    Isis_June 2014 Update 2.4 MB

Stock Quote

 (Common Stock) Exchange  (US Dollar) Change(%)  :
Volume  :

Data as of 04/20/18 12:19 pm EDT
Copyright Nasdaq. Minimum 15 minutes delayed.
Feature report

 

2016 Annual Report

2016 Annual Report

04/13/17
( FY 2017 )
2016 Annual Report 3.7 MB

Receive E-mail Alerts

Required fields denoted by an asterisk ().
Alert type

Primary IR Contact

D. Wade Walke, Ph.D.
Vice President, Corporate Communications and Investor Relations
Ionis Pharmaceuticals, Inc.
Phone: 760-603-2331
                               
©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.
  • Home
  • Contact
  • Terms of Use and FLS
  • About
    • Mission & Values
    • In The Community
    • Management
    • Board of Directors
    • Contact
  • R&D
    • Antisense Technology
      • Discovery Platform
      • Basic Science
      • Antisense Drugs
      • Medicinal Chemistry
      • Antisense Approaches
    • Intellectual Property
    • Strategic Alliances
      • Pharmaceutical Partners
      • Satellite Companies
  • Pipeline
  • Patients
    • Patient Resources
    • Clinical Trials
      • Drug Approval Process
  • Medical Professionals
    • ATTR Expanded Access Program
  • Investors & Media
    • News & Events
      • Press Releases
      • Archived Webcasts
      • Event Calendar
    • Corporate Governance
      • Board of Directors
      • Board Criteria
      • Director Compensation and Board Meeting Attendance
      • Committee Composition
      • Certificates of Incorporation
      • Bylaws
      • Code of Ethics
      • Clawback Policy
      • RSU Holding Guidelines
      • Annual Meeting
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Analyst Coverage
      • Ownership Profile
    • Financials
      • Annual Reports
      • SEC Filings
    • Shareholder Services
      • Investor FAQ
      • Information Request
  • Careers
    • Available Positions
      • Search Open Jobs
      • Browse Open Jobs
      • Edit Your Profile
      • View Submitted Applications
    • Culture & Core Principles
    • Benefits
    • Equal Opportunity
    • Intern Program
    • Post-Doctoral Program
SPINRAZA Demonstrated Motor Function Improvements in Infants on Permanent Ventilation; No Increase in Risk of Adverse Events in Children with Scoliosis Biogen Highlights SPINRAZA Data at the Cure SMA 2017 Annual SMA Conference June 29, 2017 07:30 AM Eastern Daylight Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) will present robust efficacy and safety data from Phase 2 and 3 SPINRAZA® (nusinersen) studies at the Cure SMA 2017 ... 
CARLSBAD, Calif., June 22, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the completion of enrollment in the Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in patients with Huntington's disease (HD). Dosing in the final patient cohort continues, and Ionis plans to report top-line results from this study around year-end 2017. The safety and tolerability profile of IONIS-HTTRx in the completed cohorts of the Phase 1/2a study suppor... 
CAMBRIDGE, Mass., June 20, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced that it has launched the proposed initial public offering of its common stock. Akcea is offering 9,620,000 shares of common stock and the underwriters will have a 30-day option to purchase up to an additional 1,443,000 shares of common stock. The initial public offering price is currently expected to be between $12.00 and $14.00 per share.  Akcea has applied to list the s... 
First Approved Treatment in EU for SMA Approved to Treat Broad Range of People with SMA Ionis Earns $50 Million Milestone CARLSBAD, Calif., June 1, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the European Commission (EC) has granted marketing authorization for SPINRAZA® (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA). 5q SMA is the most common form of the disease and represents approximately 95% of all SMA cases. SPINRAZA is th...